Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04TNT
|
|||
| Former ID |
DNCL002937
|
|||
| Drug Name |
ABT-639
|
|||
| Synonyms |
ABT-639; 1235560-28-7; ABT 639; UNII-0G7D0CQ88I; ABT639; 0G7D0CQ88I; CHEMBL3589557; ABT-639 free base; SCHEMBL400073; GTPL7721; CHEMBL3590674; AGPIHNZOZNKRGT-CYBMUJFWSA-N; MolPort-046-033-584; EX-A1021; BCP17732; BDBM50095309; ZINC113741875; AKOS030526344; SB19105; CS-5515; HY-19721; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylcarbonyl]benzenesulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 2 | [1], [2] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C20H20ClF2N3O3S
|
|||
| Canonical SMILES |
C1CC2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F
|
|||
| InChI |
1S/C20H20ClF2N3O3S/c21-15-11-17(23)19(30(28,29)24-18-6-2-1-5-16(18)22)10-14(15)20(27)26-9-8-25-7-3-4-13(25)12-26/h1-2,5-6,10-11,13,24H,3-4,7-9,12H2/t13-/m1/s1
|
|||
| InChIKey |
AGPIHNZOZNKRGT-CYBMUJFWSA-N
|
|||
| CAS Number |
CAS 1235560-28-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) | Target Info | Modulator | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | NCAM1 interactions | |||
| WikiPathways | Corticotropin-releasing hormone | |||
| NCAM signaling for neurite out-growth | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7721). | |||
| REF 2 | Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.